Market Place
Sourcing Support
Halozyme beefs up drug delivery franchise with $1B deal
14 Apr 2022 //
FIERCEPHARMA
Antares Pharma Announces FDA Approval Of TLANDO
29 Mar 2022 //
GLOBENEWSWIRE
Antares Pharma Reports Q4 and Full-Year 2021 Financial and Operating Results
03 Mar 2022 //
GLOBENEWSWIRE
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
28 Feb 2022 //
GLOBENEWSWIRE
Lipocine`s Partner Received FDA Acceptance Of NDA Resubmission For Tlando
03 Feb 2022 //
PRNEWSWIRE
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
03 Feb 2022 //
GLOBENEWSWIRE
Antares Pharma Receives FDA FTD for ATRS-1902 for Adrenal Crisis Rescue
18 Jan 2022 //
GLOBENEWSWIRE
Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902
11 Jan 2022 //
GLOBENEWSWIRE
Antares Pharma develops novel auto-injector devices
10 Jan 2022 //
FIERCEPHARMA
Antares Pharma to Participate in the Piper Sandler 33rd AVHC
22 Nov 2021 //
GLOBENEWSWIRE
Lipocine Announces Financial Results for Q3 Ended September 30, 2021
10 Nov 2021 //
PRNEWSWIRE
Antares Pharma to Present at the Jefferies London Healthcare Conference
10 Nov 2021 //
GLOBENEWSWIRE
Antares Pharma Announces Oral Presentation at the 22nd Annual Fall
25 Oct 2021 //
GLOBENEWSWIRE
Antares Pharma Enters into Exclusive License Agreement With Lipocine TLANDO®
18 Oct 2021 //
GLOBENEWSWIRE
Lipocine and Antares Pharma enter agreement to commercialise TLANDO®
18 Oct 2021 //
PHARMAFILE
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
28 Jul 2021 //
GLOBENEWSWIRE
Antares Pharma FDA Acceptance of IND Application for ATRS-1902
22 Jul 2021 //
GLOBENEWSWIRE
Antares Pharma FDA Acceptance of IND Application for ATRS-1902
22 Jul 2021 //
GLOBENEWSWIRE
Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference
07 Jul 2021 //
GLOBENEWSWIRE
Idorsia Initiates the Ph 3 Study With Selatogrel for Acute Myocardial Infarction
28 Jun 2021 //
GLOBENEWSWIRE
Antares Pharma Announces Submission of IND Application for ATRS-1902
22 Jun 2021 //
GLOBENEWSWIRE
Antares Pharma to Present at Raymond James Human Health Innovations Conference
15 Jun 2021 //
GLOBENEWSWIRE
Antares Vision Agrees to Acquire rfXcel Corporation
19 Feb 2021 //
CONTRACTPHARMA
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals
01 Oct 2020 //
GLOBENEWSWIRE
Antares & Lunatus Enter Into an Exclusive Distribution Agreement for XYOSTED®
03 Aug 2020 //
GLOBENEWSWIRE
First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Europe
21 Jul 2020 //
GLOBENEWSWIRE
Antares Vision Grows Portfolio of AI-Based Data Monitoring Software
06 Jul 2020 //
CONTRACTPHARMA
Antares Enters Into Global Development Agreement With Idorsia Pharmaceuticals
20 Nov 2019 //
BIOSPACE
Antares Enters Into Global Development Agreement With Idorsia Pharmaceuticals
20 Oct 2019 //
BIOSPACE
Antares Enters Into Global Development Agreement With Idorsia Pharmaceuticals
20 Oct 2019 //
BIOSPACE
Wotton named CEO of cell, gene therapy startup Obsidian
18 Apr 2019 //
FIERCE BIOTECH
Antares Pharma`s testosterone drug gets FDA approval
03 Oct 2018 //
REUTERS
Antares gains FDA OK for testosterone injection on second try
02 Oct 2018 //
ENDPTS
FDA Action Alert: Merck, Insmed and Antares Pharma
24 Sep 2018 //
Antares Pharma Provides XYOSTED™ Regulatory Update
05 Apr 2018 //
GLOBENEWSWIRE
Antares Pharma to Present at the Raymond James & Associates 39thConference
26 Feb 2018 //
GLOBENEWSWIRE
After Heavy Losses, Can Antares Pharma Bounce Back?
18 Oct 2017 //
SEEKING ALPHA
Antares Pharma (ATRS) Implodes After FDA Responds to Its Xyosted NDA
13 Oct 2017 //
BIOSPACE
Egalet Corporation Appoints Robert Roche to Board of Directors
08 Dec 2016 //
PR NEWSWIRE
Antares Pharma Appoints a New CEO
26 Jan 2016 //
BIOSPACE
